BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26460064)

  • 1. Breakthrough candidaemia in the era of broad-spectrum antifungal therapies.
    Cuervo G; Garcia-Vidal C; Nucci M; Puchades F; Fernández-Ruiz M; Obed M; Manzur A; Gudiol C; Pemán J; Aguado JM; Ayats J; Carratalà J
    Clin Microbiol Infect; 2016 Feb; 22(2):181-188. PubMed ID: 26460064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study.
    Breda GL; Tuon FF; Meis JF; Herkert PF; Hagen F; de Oliveira LZ; Dias VC; da Cunha CA; Queiroz-Telles F
    Med Mycol; 2018 Jun; 56(4):406-415. PubMed ID: 29420820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis.
    Posteraro B; De Carolis E; Criscuolo M; Ballanti S; De Angelis G; Del Principe MI; Delia M; Fracchiolla N; Marchesi F; Nadali G; Picardi M; Piccioni AL; Verga L; Candoni A; Busca A; Sanguinetti M; Pagano L;
    Mycoses; 2020 Sep; 63(9):900-910. PubMed ID: 32531854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
    Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
    Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010.
    Chen CY; Huang SY; Tsay W; Yao M; Tang JL; Ko BS; Chou WC; Tien HF; Hsueh PR
    Int J Antimicrob Agents; 2012 Dec; 40(6):533-8. PubMed ID: 23006521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
    Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
    Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
    J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal resistance in patients with Candidaemia: a retrospective cohort study.
    Aldardeer NF; Albar H; Al-Attas M; Eldali A; Qutub M; Hassanien A; Alraddadi B
    BMC Infect Dis; 2020 Jan; 20(1):55. PubMed ID: 31952505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
    Oxman DA; Chow JK; Frendl G; Hadley S; Hershkovitz S; Ireland P; McDermott LA; Tsai K; Marty FM; Kontoyiannis DP; Golan Y
    J Antimicrob Chemother; 2010 Jul; 65(7):1460-5. PubMed ID: 20430790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain.
    Puig-Asensio M; Ruiz-Camps I; Fernández-Ruiz M; Aguado JM; Muñoz P; Valerio M; Delgado-Iribarren A; Merino P; Bereciartua E; Fortún J; Cuenca-Estrella M; Almirante B; ; ;
    Clin Microbiol Infect; 2015 May; 21(5):491.e1-10. PubMed ID: 25703212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
    Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies.
    Gamaletsou MN; Walsh TJ; Zaoutis T; Pagoni M; Kotsopoulou M; Voulgarelis M; Panayiotidis P; Vassilakopoulos T; Angelopoulou MK; Marangos M; Spyridonidis A; Kofteridis D; Pouli A; Sotiropoulos D; Matsouka P; Argyropoulou A; Perloretzou S; Leckerman K; Manaka A; Oikonomopoulos P; Daikos G; Petrikkos G; Sipsas NV
    Clin Microbiol Infect; 2014 Jan; 20(1):O50-7. PubMed ID: 23889746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
    Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
    J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes.
    Grim SA; Berger K; Teng C; Gupta S; Layden JE; Janda WM; Clark NM
    J Antimicrob Chemother; 2012 Mar; 67(3):707-14. PubMed ID: 22184469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
    Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
    J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains.
    Cuervo G; Puig-Asensio M; Garcia-Vidal C; Fernández-Ruiz M; Pemán J; Nucci M; Aguado JM; Salavert M; González-Romo F; Guinea J; Zaragoza O; Gudiol C; Carratalà J; Almirante B; ;
    Clin Microbiol Infect; 2015 Jul; 21(7):684.e1-9. PubMed ID: 25765773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.
    Shah DN; Yau R; Weston J; Lasco TM; Salazar M; Palmer HR; Garey KW
    J Antimicrob Chemother; 2011 Sep; 66(9):2146-51. PubMed ID: 21700622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008.
    Pfaller M; Neofytos D; Diekema D; Azie N; Meier-Kriesche HU; Quan SP; Horn D
    Diagn Microbiol Infect Dis; 2012 Dec; 74(4):323-31. PubMed ID: 23102556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.
    Arendrup MC; Dzajic E; Jensen RH; Johansen HK; Kjaeldgaard P; Knudsen JD; Kristensen L; Leitz C; Lemming LE; Nielsen L; Olesen B; Rosenvinge FS; Røder BL; Schønheyder HC
    Clin Microbiol Infect; 2013 Aug; 19(8):E343-53. PubMed ID: 23607326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.